Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration‐resistant prostate cancer

Baseline or acquired resistance to docetaxel (DOC) represents a significant risk for patients with metastatic prostate cancer (PC). In the last years, novel therapy regimens have been approved providing reasonable alternatives for DOC‐resistant patients making prediction of DOC resistance of great c...

Descripción completa

Detalles Bibliográficos
Autores principales: Keresztes, Dávid, Csizmarik, Anita, Nagy, Nikolett, Módos, Orsolya, Fazekas, Tamás, Bracht, Thilo, Sitek, Barbara, Witzke, Kathrin, Puhr, Martin, Sevcenco, Sabina, Kramer, Gero, Shariat, Shahrokh, Küronya, Zsófia, Takács, László, Tornyi, Ilona, Lázár, József, Hadaschik, Boris, Lászik, András, Szűcs, Miklós, Nyirády, Péter, Szarvas, Tibor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831956/
https://www.ncbi.nlm.nih.gov/pubmed/34970839
http://dx.doi.org/10.1111/jcmm.17141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831956/
https://www.ncbi.nlm.nih.gov/pubmed/34970839
http://dx.doi.org/10.1111/jcmm.17141

Ejemplares similares